Clinical Trial Update: GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating GM1 prophylaxis to prevent chemotherapy-induced cognitive impairment in patients with early operable breast cancer has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Cognitive Impairment

Drugs mentioned

• GM1 Prophylaxis (GM1 ganglioside)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Chemotherapy-Related Cognitive Impairment, Breast Cancer | Phase 3 | Status: TERMINATED